Tecentriq Demonstrates Survival Benefit in ctDNA-Guided Bladder Cancer Treatment at ESMO 2025

Tecentriq (atezolizumab) significantly reduced the risk of death (overall survival) by 41% and the risk of disease recurrence or death (disease-free survival) by 36% compared with placebo in a ctDNA-guided setting for muscle-invasive bladder cancer (MIBC) patients post-surgery2 6 4 10.

Results come from the phase III IMvigor011 trial, the first global study to use ctDNA-guided therapy in this cancer type2 3 7.

Only patients with detectable circulating tumor DNA (ctDNA) after cystectomy were given Tecentriq, allowing individuals at low recurrence risk (undetectable ctDNA) to avoid unnecessary treatment and side effects2 4.

Median overall survival was 32.8 months for Tecentriq versus 21.1 months for placebo (HR=0.59, 95% CI:
0.39-0.90, p=0.0131)2.

Median disease-free survival (DFS) was 9.9 months with Tecentriq compared to 4.8 months with placebo (HR=0.64, 95% CI:
0.47-0.87, p=0.0047)2.

The ctDNA test used was the Signatera™ molecular residual disease (MRD) assay2.

The trial results support a personalized approach in post-surgical bladder cancer treatment, as ctDNA testing can identify patients who benefit most from adjuvant immunotherapy2 4.

The safety profile of Tecentriq was consistent with prior studies in bladder cancer2.

These findings were presented at the Presidential Symposium at the ESMO Congress 2025 and will be discussed with regulatory authorities2 4.